49 results
8-K
EX-1.1
SAGE
Sage Therapeutics Inc
7 Nov 23
Entry into a Material Definitive Agreement
7:39am
stock or other equity interest in the Company or any of its subsidiaries, or any contract, commitment, agreement, understanding or arrangement of any
424B5
SAGE
Sage Therapeutics Inc
7 Nov 23
Prospectus supplement for primary offering
7:29am
supplement, on a firm commitment basis.
The distribution of the securities may be effected from time to time in one or more transactions:
at a fixed
8-K
EX-99.1
dzs8z4w92 wayi
7 Nov 23
Sage Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
6:46am
8-K
EX-99.1
5xtfl
14 Jul 22
In the Court of Chancery of the State of Delaware
4:08pm
S-3ASR
y3e3v
17 Dec 21
Automatic shelf registration
12:00am
8-K
EX-99.1
rvov4uhsy2auvhk 5m
12 Apr 21
Sage Therapeutics and Biogen Announce SAGE-324 Phase 2 Placebo-Controlled KINETIC Study in Essential Tremor Met Primary Endpoint
7:17am